FIELD: chemistry.
SUBSTANCE: invention relates to crystalline form I (3aR,5s,6aS)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl(7H-pyrrolo[2,3-d]pyrimidine-4-yl)amino)hexahydrocyclopent[c]pyrrol-2(1H)-formamide bisulphate, characterized in that the crystal has a powder X-ray diffraction pattern, obtained using Cu-Kα radiation and characterized by angles 2θ and interplanar distances, as shown in Fig. 1, containing characteristic peaks at approximately 6.38 (13.85), 10.38 (8.51), 10.75 (8.23), 14.49 (6.11), 15.07 (5.88), 15.58 (5.69), 16.23 (5.46), 17.84 (4.97), 18.81 (4.72), 19.97 (4.44), 20.77 (4.27), 22.12 (4.02), 23.19 (3.83), 24.12 (3.69), 25.51 (3.49), 26.62 (3.35), 27.38 (3.26), 28.56 (3.12) and 29.91 (2.99).
EFFECT: compound of formula (I) in a crystalline form is intended for preparing a medicinal agent for treating JAK disease, such as rheumatoid arthritis and rheumatoid arthritis.
5 cl, 4 dwg, 1 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CRYSTALLINE FORM OF BISULPHATE JAK-KINASE INHIBITOR AND A METHOD FOR PRODUCTION THEREOF | 2015 |
|
RU2716260C2 |
| BISULFATE OF JANUS KINAZE (JAK) INHIBITOR AND METHOD FOR ITS PREPARATION | 2014 |
|
RU2665680C2 |
| PHARMACEUTICAL COMPOSITION INCLUDING JANUS KINASE INHIBITOR OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 2017 |
|
RU2744432C2 |
| DERIVATIVES OF PYRROLOPYRIMIDINE USEFUL AS JAK-KINASES INHIBITORS | 2012 |
|
RU2618673C2 |
| PYRAZOLE-BASED MAGL INHIBITORS | 2018 |
|
RU2789157C2 |
| PHENYL AMINO PYRIMIDINE COMPOUND OR POLYMORPH OF SALT THEREOF | 2016 |
|
RU2712226C2 |
| HETEROCYCLIC COMPOUNDS FOR TYROSINE KINASE 2 ACTIVITY MEDIATION | 2020 |
|
RU2826012C2 |
| RMT5 INHIBITORS | 2019 |
|
RU2814198C2 |
| PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES | 2009 |
|
RU2493157C2 |
| CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DESTRUCTION OF ANDROGEN RECEPTORS AND USE THEREOF | 2020 |
|
RU2825000C2 |
